| pubmed-article:12151191 | pubmed:abstractText | The antimicrobial activity of garenoxacin, a des-(6)F quinolone (formally BMS284756 and T-3811), was evaluated against 2,537 skin and soft tissue infection (SSTI) isolates from the SENTRY Antimicrobial Surveillance Program. Strains isolated in 2000 from Europe, North and Latin America were tested at a central laboratory using reference broth microdilution methods. The rank order of the seven most frequent SSTI pathogens was: Staphylococcus aureus (39.9%), Pseudomonas aeruginosa (12.1%), Escherichia coli (9.7%), Enterococcus spp. (7.7%), Klebsiella spp. (5.8%), Enterobacter spp. (5.6%) and coagulase-negative staphylococci (CoNS; 4.2%). Garenoxacin exhibited a four-fold greater activity (MIC(90), 0.06 microg/ml) compared to levofloxacin (MIC(90), 0.25 microg/ml) against oxacillin-susceptible S. aureus; and oxacillin-resistant staphylococci were more susceptible to garenoxacin (>/=90.5%) at </=4 microg/ml than ciprofloxacin or levofloxacin. Enterococcus spp. were more susceptible to garenoxacin and gatifloxacin (MIC(50), 0.5 microg/ml) than ciprofloxacin or levofloxacin (MIC(50), 2 microg/ml). All tested quinolones inhibited 64.7 to 69.7% of P. aeruginosa isolates, and the rank order of potency slightly favored ciprofloxacin (MIC(50), </=0.25 microg/ml). Similar susceptibility rates for the four quinolones were observed against E. coli (85.8-87.0%), Enterobacter spp. (90.8-94.3%) and Klebsiella spp. (89.8-95.2%) with the greatest levels of resistance recorded in Latin America for E. coli and Enterobacter spp. The occurrence of extended spectrum beta-lactamase-producing isolates (predominantly K. pneumoniae) was documented in all three monitored regions (Latin America > Europe > North America). Continued development of garenoxacin as a treatment of pathogens that commonly cause SSTIs appears to be warranted. | lld:pubmed |
